Clin2
NCT06775860Possibly a fitRecruiting

Testing ICP-332 for moderate to severe eczema

Atopic Dermatitis

Treatments studied

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
552 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have had eczema (atopic dermatitis) for at least 1 year.
  • Topical treatments like creams haven't worked well enough or aren't right for you.
  • Your eczema covers at least 10% of your body and is causing significant itching.
  • You have not taken a JAK inhibitor for eczema before without it working.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07239947Recruiting· Phase 1
Testing BBT001 for healthy volunteers and people with eczema

This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.

Hefei, Anhui
NCT07399067Recruiting· Phase 2
Testing IBI3002 for moderate to severe eczema

This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.

Beijing, Beijing Municipality
NCT07015762Recruiting· Phase 1
Testing IBI3002 for moderate-to-severe eczema

This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.

Suzhou, Jiangsu
NCT07549984Not yet recruiting· Phase 1
Testing IBI3033 for Moderate-to-Severe Atopic Dermatitis

This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.

Hangzhou, Hangzhou
NCT06055361Recruiting· Phase 1
Studying a new injection for moderate to severe eczema

This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.

North Little Rock, Arkansas
NCT06487000Not yet recruiting· Phase 2
Testing EC-18 for moderate to severe eczema

This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.

Hear when a new Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.